KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Cme (CME) EBITDA (2016 - 2025)

Historic EBITDA for Cme (CME) over the last 17 years, with Q3 2025 value amounting to $999.0 million.

  • Cme's EBITDA fell 507.41% to $999.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.2 billion, marking a year-over-year increase of 771.11%. This contributed to the annual value of $3.9 billion for FY2024, which is 1443.08% up from last year.
  • As of Q3 2025, Cme's EBITDA stood at $999.0 million, which was down 507.41% from $1.2 billion recorded in Q2 2025.
  • In the past 5 years, Cme's EBITDA ranged from a high of $1.2 billion in Q2 2025 and a low of $631.7 million during Q4 2021
  • Moreover, its 5-year median value for EBITDA was $870.9 million (2023), whereas its average is $879.7 million.
  • Per our database at Business Quant, Cme's EBITDA tumbled by 2336.21% in 2021 and then surged by 2916.35% in 2023.
  • Over the past 5 years, Cme's EBITDA (Quarter) stood at $631.7 million in 2021, then grew by 5.79% to $668.3 million in 2022, then rose by 29.16% to $863.2 million in 2023, then rose by 9.72% to $947.1 million in 2024, then grew by 5.48% to $999.0 million in 2025.
  • Its EBITDA stands at $999.0 million for Q3 2025, versus $1.2 billion for Q2 2025 and $1.1 billion for Q1 2025.